Report cover image

Biomarkers Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Jan 01, 2025
Length 110 Pages
SKU # FOB19847126

Description

Growth Factors of Biomarkers Market

Introduction

Biomarkers have become a crucial component in modern healthcare, playing a vital role in disease diagnosis, drug development, and personalized medicine. The global biomarkers market is witnessing rapid growth, driven by advancements in biotechnology, increased investments in research, and the rising prevalence of chronic diseases such as cancer and cardiovascular conditions.

Market Overview

According tthe latest market research, the global biomarkers market was valued at $38.41 billion in 2018 and is expected treach $190.81 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.1%. This significant expansion can be attributed tthe increasing application of biomarkers in clinical research, diagnostics, and therapeutics.

Key Growth Drivers

1. Rising Prevalence of Chronic Diseases

Chronic diseases such as cancer, diabetes, and cardiovascular disorders are among the leading causes of death worldwide. Biomarkers help in early detection, enabling timely intervention and better treatment outcomes. For instance, cancer biomarkers like PSA (prostate-specific antigen) and HER2 (human epidermal growth factor receptor 2) are widely used in oncology diagnostics.

2. Advancements in Biotechnology and Genomics

Breakthroughs in genomics, proteomics, and molecular biology have revolutionized biomarker discovery. High-throughput screening techniques, next-generation sequencing (NGS), and artificial intelligence (AI)-driven analytics have accelerated biomarker identification, improving diagnostic accuracy and personalized treatment strategies.

3. Increased Investments in Research and Development (R&D)

Governments and private organizations are heavily investing in biomarker research tdevelop innovative diagnostic tools and targeted therapies. The pharmaceutical and biotechnology sectors are leveraging biomarkers tenhance drug development efficiency and reduce clinical trial costs.

4. Growing Demand for Personalized Medicine

Biomarkers are at the forefront of personalized medicine, enabling tailored treatment approaches based on individual genetic profiles. This trend is particularly prominent in oncology, where precision medicine is transforming cancer care by identifying patients most likely tbenefit from specific treatments.

Market Segmentation

The biomarkers market is segmented based on:
  • Type: Safety biomarkers, efficacy biomarkers, and validation biomarkers
  • Application: Drug discovery & development, diagnostics, personalized medicine, and disease risk assessment
  • End Users: Pharmaceutical & biotechnology companies, research institutions, and diagnostic labs
Among these, diagnostics and drug discovery represent the largest market segments due ttheir crucial role in early disease detection and drug efficacy assessment.

Regional Insights

1. North America

North America dominates the biomarkers market, driven by a strong healthcare infrastructure, high R&D spending, and the presence of leading pharmaceutical companies. The U.S. leads in biomarker-based drug development and regulatory approvals.

2. Europe

Europe holds a significant market share, with increasing government initiatives supporting biomarker research. Countries like Germany, the U.K., and France are at the forefront of precision medicine and biomarker-driven diagnostics.

3. Asia-Pacific

The Asia-Pacific region is witnessing the fastest growth, fueled by rising healthcare expenditure, expanding biotech industries, and growing awareness about personalized medicine. China and India, in particular, are emerging as key players in biomarker research.

Challenges and Future Outlook

Despite the promising growth, the biomarkers market faces challenges such as:
  • High costs of biomarker discovery and validation
  • Regulatory complexities and approval delays
  • Limited standardization in biomarker testing
However, with continued technological advancements, strategic collaborations, and increasing focus on precision medicine, the biomarkers market is set tplay a pivotal role in the future of healthcare.

Conclusion

The biomarkers market is on a remarkable growth trajectory, transforming disease diagnostics, drug development, and patient care. With ongoing R&D, technological innovations, and global healthcare initiatives, biomarkers will continue tshape the future of personalized medicine and precision healthcare.

ATTRIBUTE DETAILS

Study Period - 2015-2026

Base Year - 2018

Forecast Period - 2019-2026

Historical Period - 2015-2017

Unit - Value (USD billion)

By Indication
  • Oncology
  • Cardiology
  • Neurology
  • Others
By End User
  • Pharmaceutical & Biotechnology Companies
  • Diagnostics & Research Laboratories
  • Hospitals & Specialty Clinics
  • Others
By Geography
  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

110 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. New Product Launches, by Key Market Players
4.2. Prevalence by Disease Indication, By Key Countries/ Region, 2018
4.3. Incidence of Cancer, By Key Countries/ Key Region,2018
4.4. Key industry Developments - Mergers, Acquisitions and Partnerships
4.5. Overview of Biomarkers In Personalized Medicine
5. Global Biomarkers Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Indication
5.2.1. Oncology
5.2.2. Cardiology
5.2.3. Neurology
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By End User
5.3.1. Pharmaceutical & Biotechnology Companies
5.3.2. Diagnostics & Research Laboratories
5.3.3. Hospitals & Specialty Clinics
5.3.4. Others
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Latin America
5.4.5. Middle East & Africa
6. North America Biomarkers Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast – By Indication
6.2.1. Oncology
6.2.2. Cardiology
6.2.3. Neurology
6.2.4. Others
6.3. Market Analysis, Insights and Forecast – By End User
6.3.1. Pharmaceutical & Biotechnology Companies
6.3.2. Diagnostics & Research Laboratories
6.3.3. Hospitals & Specialty Clinics
6.3.4. Others
6.4. Market Analysis, Insights and Forecast – By Country
6.4.1. U.S.
6.4.2. Canada
7. Europe Biomarkers Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast – By Indication
7.2.1. Oncology
7.2.2. Cardiology
7.2.3. Neurology
7.2.4. Others
7.3. Market Analysis, Insights and Forecast – By End User
7.3.1. Pharmaceutical & Biotechnology Companies
7.3.2. Diagnostics & Research Laboratories
7.3.3. Hospitals & Specialty Clinics
7.3.4. Others
7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Spain
7.4.5. Italy
7.4.6. Scandinavia
7.4.7. Rest of Europe
8. Asia Pacific Biomarkers Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast – By Indication
8.2.1. Oncology
8.2.2. Cardiology
8.2.3. Neurology
8.2.4. Others
8.3. Market Analysis, Insights and Forecast – By End User
8.3.1. Pharmaceutical & Biotechnology Companies
8.3.2. Diagnostics & Research Laboratories
8.3.3. Hospitals & Specialty Clinics
8.3.4. Others
8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Southeast Asia
8.4.6. Rest of Asia Pacific
9. Latin America Biomarkers Market Analysis, Insights and Forecast, 2015-2026
9.1. Key Findings / Summary
9.2. Market Analysis, Insights and Forecast – By Indication
9.2.1. Oncology
9.2.2. Cardiology
9.2.3. Neurology
9.2.4. Others
9.3. Market Analysis, Insights and Forecast – By End User
9.3.1. Pharmaceutical & Biotechnology Companies
9.3.2. Diagnostics & Research Laboratories
9.3.3. Hospitals & Specialty Clinics
9.3.4. Others
9.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
10. Middle East & Africa Biomarkers Market Analysis, Insights and Forecast, 2015-2026
10.1. Key Findings / Summary
10.2. Market Analysis, Insights and Forecast – By Indication
10.2.1. Oncology
10.2.2. Cardiology
10.2.3. Neurology
10.2.4. Others
10.3. Market Analysis, Insights and Forecast – By End User
10.3.1. Pharmaceutical & Biotechnology Companies
10.3.2. Diagnostics & Research Laboratories
10.3.3. Hospitals and Specialty Clinics
10.3.4. Others
10.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
10.4.1. GCC Countries
10.4.2. South Africa
10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2018)
11.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
11.3.1. F. Hoffmann-La Roche Ltd.
11.3.1.1. Overview,
11.3.1.2. Products & services,
11.3.1.3. SWOT analysis,
11.3.1.4. Recent developments,
11.3.1.5. strategies,
11.3.1.6. financials (based on availability)
11.3.2. Abbott
11.3.2.1. Overview,
11.3.2.2. Products & services,
11.3.2.3. SWOT analysis,
11.3.2.4. Recent developments,
11.3.2.5. strategies,
11.3.2.6. financials (based on availability)
11.3.3. Thermo Fisher Scientific
11.3.3.1. Overview,
11.3.3.2. Products & services,
11.3.3.3. SWOT analysis,
11.3.3.4. Recent developments,
11.3.3.5. strategies,
11.3.3.6. financials (based on availability)
11.3.4. Bio-Rad Laboratories, Inc
11.3.4.1. Overview,
11.3.4.2. Products & services,
11.3.4.3. SWOT analysis,
11.3.4.4. Recent developments,
11.3.4.5. strategies,
11.3.4.6. financials (based on availability)
11.3.5. CENTOGENE N.V.
11.3.5.1. Overview,
11.3.5.2. Products & services,
11.3.5.3. SWOT analysis,
11.3.5.4. Recent developments,
11.3.5.5. strategies,
11.3.5.6. financials (based on availability)
11.3.6. Axon Medchem
11.3.6.1. Overview,
11.3.6.2. Products & services,
11.3.6.3. SWOT analysis,
11.3.6.4. Recent developments,
11.3.6.5. strategies,
11.3.6.6. financials (based on availability)
11.3.7. Sino Biological Inc.
11.3.7.1. Overview,
11.3.7.2. Products & services,
11.3.7.3. SWOT analysis,
11.3.7.4. Recent developments,
11.3.7.5. strategies,
11.3.7.6. financials (based on availability)
11.3.8. R&D System
11.3.8.1. Overview,
11.3.8.2. Products & services,
11.3.8.3. SWOT analysis,
11.3.8.4. Recent developments,
11.3.8.5. strategies,
11.3.8.6. financials (based on availability)
11.3.9. BioVision Inc.
11.3.9.1. Overview,
11.3.9.2. Products & services,
11.3.9.3. SWOT analysis,
11.3.9.4. Recent developments,
11.3.9.5. strategies,
11.3.9.6. financials (based on availability)
11.3.10. Myriad RBM
11.3.10.1. Overview,
11.3.10.2. Products & services,
11.3.10.3. SWOT analysis,
11.3.10.4. Recent developments,
11.3.10.5. strategies,
11.3.10.6. financials (based on availability)
11.3.11. Other Prominent Players
11.3.11.1. Overview,
11.3.11.2. Products & services,
11.3.11.3. SWOT analysis,
11.3.11.4. Recent developments,
11.3.11.5. strategies,
11.3.11.6. financials (based on availability)
12. Strategic Recommendation

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us